Development of a Novel Recombinant Disintegrin, Contortrostatin, as an Effective Anti-Tumor and Anti-Angiogenic Agent

Publisher： Karger

E-ISSN： 1424-8840|34|4-5|177-183

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.34, Iss.4-5, 2006-05, pp. : 177-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Contortrostatin, a Snake Venom Disintegrin with Anti-Angiogenic and Anti-Tumor Activity

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 34, Iss. 4-5, 2006-05 ,pp. : 169-176

Karger

Access to resources Recommend Favorite

Anti-angiogenic therapy in breast cancer

By Atiqur Rahman M.   Toi M.  

Biomedicine and Pharmacotherapy, Vol. 57, Iss. 10, 2003-12 ,pp. : 463-470

Elsevier

Access to resources Recommend Favorite

Anti‐angiogenic activity of PSA‐derived peptides

By  

THE PROSTATE, Vol. 75, Iss. 12, 2015-07 ,pp. : 1285-1299

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 114, Iss. 3, 2005-10 ,pp. : 170-173

Karger

Access to resources Recommend Favorite

EPH receptor/ephrin system: in the quest for novel anti‐angiogenic therapies: Commentary on Hassan‐Mohamed et al., Br J Pharmacol 171: 5195–5208

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 18, 2015-09 ,pp. : 4597-4599

John Wiley & Sons Inc

Access to resources Recommend Favorite